<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02369406</url>
  </required_header>
  <id_info>
    <org_study_id>U01AI114235</org_study_id>
    <nct_id>NCT02369406</nct_id>
  </id_info>
  <brief_title>Early Infant HIV Treatment in Botswana</brief_title>
  <acronym>EIT</acronym>
  <official_title>BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvard School of Public Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ragon Institute of MGH, MIT and Harvard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Harvard School of Public Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to determine whether very early antiretroviral
      treatment (ART) initiation in HIV-infected infants limits the seeding of viral reservoirs and
      maintains immune responses, potentially allowing future periods off ART.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV-1 infection during adulthood leads to a stable, long-lasting viral reservoir in CD4 T
      cells that persists despite suppressive antiretroviral therapy (ART), and is responsible for
      rapid viral rebound once treatment is stopped in most cases. In neonates, HIV-1 infection
      occurs at a time when the adaptive immune system is still in development, which may alter the
      establishment of a long-lasting viral reservoir and offer opportunities to reduce viral
      persistence through early antiretroviral treatment. Recently, scientific understanding of
      neonatal HIV infection has been challenged by the description of an infant who tested
      positive for HIV at birth, was treated with potent combination antiretroviral therapy (ART)
      within the first 30 hours of life, and achieved long-term remission of HIV infection when ART
      was stopped approximately 18 months later. Unfortunately, after 2 years off ART, rebound
      viremia occurred in this child, yet this case raises the provocative question of whether ART
      initiated within the first days of life for an antepartum infection, or in the first
      days/weeks of life for a peripartum infection, can prevent the seeding of a long-lasting
      reservoir of HIV infected cells in some infants (and therefore lead to long periods of HIV
      remission off ART).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the proportion of infants who have treatment-limiting adverse events within the first 14 days of treatment</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the proportion of infants who fail to achieve at least a 1.5 log10 copies/mL reduction in HIV-1 RNA by the 14th day of treatment</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the proportion of infants in the antepartum cohort with trough drug concentrations below defined therapeutic ranges at 7 and 14 days of treatment (trough concentrations will be evaluated for NVP, ZDV, 3TC)</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate virologic and immunologic outcomes of very early ART in infancy</measure>
    <time_frame>192 weeks</time_frame>
    <description>Virologic outcomes after early ART: We will evaluate how the timing of HIV infection and the timing of ART initiation affect the size and composition of the viral reservoir over time.
Immunologic outcomes after early ART: We will evaluate how immune activation and immune activity against HIV-1 contribute to the size and composition of the HIV-1 reservoir over time in infants treated early with suppressive ART.
Control Group Comparisons. We will evaluate virologic and immunologic outcomes at a single time point in children for whom ART initiation was later than in the prospective cohorts, and compared with immunologic testing of stored specimens from HIV exposed uninfected and HIV unexposed children.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>HIV</condition>
  <condition>Pediatric AIDS</condition>
  <arm_group>
    <arm_group_label>Antepartum Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 children who test HIV-positive within 96 hours after birth (antepartum HIV infection) and are able to initiate ART &lt; 7 days after birth. This cohort will include at least 15 children who start ART &lt; 3 days after birth.
All infants in the antepartum cohort will initiate ART with Nevirapine, Zidovudine, Lamivudine, and later switch to Kaletra, Zidovudine, Lamivudine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Peripartum Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 children who test HIV-negative within 96 hours after birth but test HIV-positive within 42 days after birth (peripartum HIV infection) and who are able to initiate ART &lt; 57 days after birth. This cohort will include at least 10 children who start ART &lt; 21 days after birth.
The majority of infants in the peripartum cohort will be able to start Kaletra, Zidovudine, Lamivudine as their first regimen, but a minority may start Nevirapine, Zidovudine, Lamivudine and then switch to Kaletra, Zidovudine, Lamivudine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Cohort</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 HIV-infected children who initiated ART at later age ranges (30-365 days for antepartum infection, 57-365 days for peripartum infection or for those with unknown timing of infection) will be enrolled for a single visit that will occur between 24 and 36 months of age. These children will serve as a control group for virologic and immunologic comparisons with children in the prospective cohorts.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevirapine</intervention_name>
    <arm_group_label>Antepartum Cohort</arm_group_label>
    <arm_group_label>Peripartum Cohort</arm_group_label>
    <other_name>NVP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kaletra</intervention_name>
    <arm_group_label>Antepartum Cohort</arm_group_label>
    <arm_group_label>Peripartum Cohort</arm_group_label>
    <other_name>LPV/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <arm_group_label>Antepartum Cohort</arm_group_label>
    <arm_group_label>Peripartum Cohort</arm_group_label>
    <other_name>3TC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <arm_group_label>Antepartum Cohort</arm_group_label>
    <arm_group_label>Peripartum Cohort</arm_group_label>
    <other_name>ZDV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (antepartum infection cohort):

          1. Mother/guardian ≥18 years of age and able to provide informed consent

          2. Gestational age at birth ≥35 weeks

          3. Birth weight ≥2000 grams

          4. Age is less than 7 days*

          5. HIV-infection identified by testing conducted within 96 hours after birth NOTE:
             HIV-infection is defined as DNA PCR positive on at least one specimen, with
             confirmation specimen either positive or pending**

          6. Ability to initiate ART within 7 days after birth

          7. Eligible for ART through the Botswana government program

          8. Ability to be followed in BHP clinic for up to 192 weeks from enrollment

          9. Blood samples collected and submitted for real-time safety lab evaluations; results
             may be pending at the time of entry.

               -  At least half of infants in the antepartum cohort must be &lt; 3 days at enrollment,
                  including 3 of the first 6 infants enrolled.

        Inclusion Criteria (peripartum infection cohort):

          1. Mother/guardian ≥18 years of age and able to provide informed consent

          2. Age is greater than 4 days and less than 57 days

          3. HIV-negative within 96 hours after birth NOTE: HIV-negative is defined as HIV-negative
             by DNA PCR on a single specimen or HIV-negative on 2 separate confirmatory specimens
             following a re-test of an HIV-positive sample

          4. HIV-positive between 96 hours and 42 days after birth NOTE: DNA PCR positive on at
             least one specimen between 96 hour and 42 days after birth, with confirmation either
             positive or pending**

          5. Ability to initiate ART at enrollment

          6. Eligible for ART through the Botswana government program

          7. Ability to be followed in BHP clinic for ART for up to 192 weeks after enrollment

          8. Blood samples collected and submitted for real-time safety lab evaluations (results
             may be pending at the time of entry).

               -  An enrolled infant later determined to be HIV uninfected by confirmatory testing
                  will end participation in the study and this enrollment will not be counted
                  against the total number of enrollments planned.

        Inclusion Criteria (control group):

          1. Mother/guardian ≥18 years of age and able to provide informed consent

          2. 24-36 months of age

          3. HIV-infection documented within 42 days after birth

          4. ART initiated within the following timeframe based on timing of HIV-infection
             diagnosis

               -  30-365 days after birth if HIV-infection diagnosed within 96 hours after birth OR

               -  57-365 days after birth if infant was HIV-negative based on testing performed
                  within 96 hours after birth (or if unknown HIV status &lt; 96 hours from birth) and
                  then found to be HIV-positive based on testing performed between 96 hours and 42
                  days after birth.

          5. After 6 months of ART, all documented HIV RNA measurements &lt; 400 copies/mL

        Exclusion Criteria (for antepartum and peripartum infection cohort):

          1. Hospitalization for severe medical illness

          2. Medical condition making it unlikely that the infant will survive to 96 weeks

          3. If lab values are available prior to enrollment, the following Division of AIDS 2004
             results, from samples collected within 7 days prior to entry without subsequent
             testing, will exclude an infant:

               -  Grade ≥3 ALT

               -  Grade ≥3 AST

               -  Grade ≥4 hemoglobin

        Note: Baseline lab values may not be available at the time of ART start. However, as soon
        as these values are available (occasionally within &lt;24 hours), they will be used to make
        rapid treatment decisions. Neonates with baseline Grade 4 hemoglobin will be called
        immediately to ZDV discontinued if the value is confirmed. Neonates with baseline Grade 3
        or 4 ALT or AST will be called immediately to stop either NVP or LPV/r if the value is
        confirmed. Neonates who remain on ART may remain on study. Neonates who discontinue all ART
        for pre-ART laboratory abnormalities will not be counted against total enrollments.

        Exclusion Criteria (control group):

        1) &lt; 85% reported adherence to prescribed doses or interruption of ART for more than 7
        consecutive days since its initiation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>56 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roger L. Shapiro, MD, MPH</last_name>
    <phone>617-771-0040</phone>
    <email>rshapiro@hsph.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harvard School of Public Health</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ragon Institute of MGH, MIT and Harvard</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Botswana Harvard HIV/AIDS Institute Partnership</name>
      <address>
        <city>Gaborone</city>
        <country>Botswana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Makhema, MD</last_name>
      <phone>+267-390-2671</phone>
      <email>jmakhema@bhp.org.bw</email>
    </contact>
    <investigator>
      <last_name>Joseph Makhema, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Botswana</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.retroconference.org/2013b/Sessions/010.htm</url>
    <description>Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun T-W. Functional HIV cure after very early ART of an infected infant. 20th Conference on Retroviruses and Opportunistic Infections, 3 Mar 2013, Atlanta, Georgia.</description>
  </link>
  <link>
    <url>http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20110609_JC2137_Global-Plan-Elimination-HIV-Children_en.pdf</url>
    <description>Global Plan Towards The Elimination of New HIV Infections Among Children by 2015 and Keeping Their Mothers Alive 2011-2015. Joint United Nations Programme on HIV/AIDS 2011.</description>
  </link>
  <link>
    <url>http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf</url>
    <description>World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization Programme, 2013. Geneva, S</description>
  </link>
  <link>
    <url>http://www.moh.gov.bw</url>
    <description>Botswana National HIV &amp; AIDS Treatment Guidelines, 2012 Version. 1 April 2012 Edition.</description>
  </link>
  <reference>
    <citation>Munyagwa M, Baisley K, Levin J, Brian M, Grosskurth H, Maher D. Mortality of HIV-infected and uninfected children in a longitudinal cohort in rural south-west Uganda during 8 years of follow-up. Trop Med Int Health. 2012 Jul;17(7):836-43. doi: 10.1111/j.1365-3156.2012.03000.x. Epub 2012 May 16.</citation>
    <PMID>22591447</PMID>
  </reference>
  <reference>
    <citation>Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, Essex M, Ekouevi DK, Jackson D, Coutsoudis A, Kilewo C, Leroy V, Wiktor SZ, Nduati R, Msellati P, Zaba B, Ghys PD, Newell ML; UNAIDS Child Survival Group. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One. 2012;7(2):e28510. doi: 10.1371/journal.pone.0028510. Epub 2012 Feb 23.</citation>
    <PMID>22383946</PMID>
  </reference>
  <reference>
    <citation>Desmonde S, Coffie P, Aka E, Amani-Bosse C, Messou E, Dabis F, Alioum A, Ciaranello A, Leroy V. Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Côte d'Ivoire, 2004-2009. BMC Infect Dis. 2011 Jun 23;11:182. doi: 10.1186/1471-2334-11-182.</citation>
    <PMID>21699728</PMID>
  </reference>
  <reference>
    <citation>Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F; Ghent International AIDS Society (IAS) Working Group on HIV Infection in Women and Children. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004 Oct 2-8;364(9441):1236-43.</citation>
    <PMID>15464184</PMID>
  </reference>
  <reference>
    <citation>Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Veloso VG, Rossi S, Moye J, Bryson Y, Mofenson L, Camarca M, Watts DH; NICHD HPTN 040/PACTG 1043 PROTOCOL Team. Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life. Pediatr Infect Dis J. 2011 Sep;30(9):769-72. doi: 10.1097/INF.0b013e3182242950.</citation>
    <PMID>21666540</PMID>
  </reference>
  <reference>
    <citation>Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Ferrier A, Chintu C, Walker AS, Gibb DM, Burger DM. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. AIDS. 2012 Sep 10;26(14):1795-800. doi: 10.1097/QAD.0b013e32835705fd.</citation>
    <PMID>22739394</PMID>
  </reference>
  <reference>
    <citation>Mirochnick M, Best BM, Clarke DF. Antiretroviral pharmacology: special issues regarding pregnant women and neonates. Clin Perinatol. 2010 Dec;37(4):907-27, xi. doi: 10.1016/j.clp.2010.08.006. Review.</citation>
    <PMID>21078458</PMID>
  </reference>
  <reference>
    <citation>Tremoulet AH, Nikanjam M, Cressey TR, Chokephaibulkit K, McKinney R, Mirochnick M, Capparelli EV. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol. 2012 Dec;52(12):1824-32. doi: 10.1177/0091270011426563. Epub 2011 Dec 16.</citation>
    <PMID>22180560</PMID>
  </reference>
  <reference>
    <citation>Nikanjam M, Chadwick EG, Robbins B, Alvero C, Palumbo P, Yogev R, Pinto J, Hazra R, Hughes ML, Heckman BE, Capparelli EV; IMPAACT P1030 Team. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing. Clin Pharmacol Ther. 2012 Feb;91(2):243-9. doi: 10.1038/clpt.2011.218. Epub 2011 Dec 21.</citation>
    <PMID>22190064</PMID>
  </reference>
  <reference>
    <citation>Boucher FD, Modlin JF, Weller S, Ruff A, Mirochnick M, Pelton S, Wilfert C, McKinney R Jr, Crain MJ, Elkins MM, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993 Jan;122(1):137-44.</citation>
    <PMID>8419601</PMID>
  </reference>
  <reference>
    <citation>Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Tréluyer JM, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S; ANRS French Perinatal Cohort Study Group. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA. 2011 Jul 6;306(1):70-8. doi: 10.1001/jama.2011.915.</citation>
    <PMID>21730243</PMID>
  </reference>
  <reference>
    <citation>Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.</citation>
    <PMID>23516360</PMID>
  </reference>
  <reference>
    <citation>Persaud D, Palumbo PE, Ziemniak C, Hughes MD, Alvero CG, Luzuriaga K, Yogev R, Capparelli EV, Chadwick EG. Dynamics of the resting CD4(+) T-cell latent HIV reservoir in infants initiating HAART less than 6 months of age. AIDS. 2012 Jul 31;26(12):1483-90. doi: 10.1097/QAD.0b013e3283553638.</citation>
    <PMID>22555165</PMID>
  </reference>
  <reference>
    <citation>Ananworanich J, Puthanakit T, Suntarattiwong P, Chokephaibulkit K, Kerr SJ, Fromentin R, Bakeman W, Intasan J, Mahanontharit A, Sirivichayakul S, Chomont N; HIV-NAT 194 Study Group. Reduced markers of HIV persistence and restricted HIV-specific immune responses after early antiretroviral therapy in children. AIDS. 2014 Apr 24;28(7):1015-20. doi: 10.1097/QAD.0000000000000178.</citation>
    <PMID>24384692</PMID>
  </reference>
  <reference>
    <citation>Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, Busch MP, Deeks SG. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013 Jul;208(1):50-6. doi: 10.1093/infdis/jis630. Epub 2012 Oct 22.</citation>
    <PMID>23089590</PMID>
  </reference>
  <reference>
    <citation>Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sékaly RP. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009 Aug;15(8):893-900. doi: 10.1038/nm.1972. Epub 2009 Jun 21.</citation>
    <PMID>19543283</PMID>
  </reference>
  <reference>
    <citation>Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012 Mar 23;36(3):491-501. doi: 10.1016/j.immuni.2012.01.014. Epub 2012 Mar 8.</citation>
    <PMID>22406268</PMID>
  </reference>
  <reference>
    <citation>Chen H, Ndhlovu ZM, Liu D, Porter LC, Fang JW, Darko S, Brockman MA, Miura T, Brumme ZL, Schneidewind A, Piechocka-Trocha A, Cesa KT, Sela J, Cung TD, Toth I, Pereyra F, Yu XG, Douek DC, Kaufmann DE, Allen TM, Walker BD. TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol. 2012 Jun 10;13(7):691-700. doi: 10.1038/ni.2342.</citation>
    <PMID>22683743</PMID>
  </reference>
  <reference>
    <citation>Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C, Lifson JD, Allen TM, Carrington M, Altfeld M. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med. 2007 Nov 26;204(12):3027-36. Epub 2007 Nov 19.</citation>
    <PMID>18025129</PMID>
  </reference>
  <reference>
    <citation>Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, Quendler H, Kohrgruber N, Stingl G. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood. 2009 Oct 29;114(18):3854-63. doi: 10.1182/blood-2009-04-217927. Epub 2009 Aug 18.</citation>
    <PMID>19690337</PMID>
  </reference>
  <reference>
    <citation>Rout N, Greene J, Yue S, O'Connor D, Johnson RP, Else JG, Exley MA, Kaur A. Loss of effector and anti-inflammatory natural killer T lymphocyte function in pathogenic simian immunodeficiency virus infection. PLoS Pathog. 2012 Sep;8(9):e1002928. doi: 10.1371/journal.ppat.1002928. Epub 2012 Sep 20.</citation>
    <PMID>23028326</PMID>
  </reference>
  <reference>
    <citation>Autran B, Descours B, Bacchus C. Immune control of HIV-1 reservoirs. Curr Opin HIV AIDS. 2013 May;8(3):204-10. doi: 10.1097/COH.0b013e32835fe6d2. Review.</citation>
    <PMID>23493099</PMID>
  </reference>
  <reference>
    <citation>Walker BD, Yu XG. Unravelling the mechanisms of durable control of HIV-1. Nat Rev Immunol. 2013 Jul;13(7):487-98. doi: 10.1038/nri3478. Review.</citation>
    <PMID>23797064</PMID>
  </reference>
  <reference>
    <citation>Sáez-Cirión A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barré-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A; Agence Nationale de Recherches sur le Sida EP36 HIV Controllers Study Group. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81. Epub 2007 Apr 11.</citation>
    <PMID>17428922</PMID>
  </reference>
  <reference>
    <citation>Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006 Jun 15;107(12):4781-9. Epub 2006 Feb 7.</citation>
    <PMID>16467198</PMID>
  </reference>
  <reference>
    <citation>Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL; PACTG 356 Investigators. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004 Jun 10;350(24):2471-80.</citation>
    <PMID>15190139</PMID>
  </reference>
  <reference>
    <citation>Lodha R, Upadhyay A, Kabra SK. Antiretroviral therapy in HIV-1 infected children. Indian Pediatr. 2005 Aug;42(8):789-96.</citation>
    <PMID>16141480</PMID>
  </reference>
  <reference>
    <citation>Ikeda T, Ch'ng TW, Oleske JM. Recommendations in pediatric antiretroviral therapy. Expert Opin Pharmacother. 2007 Feb;8(2):155-66. Review.</citation>
    <PMID>17257086</PMID>
  </reference>
  <reference>
    <citation>Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, Chi BH, Sinkala M, Kankasa C, Wilson CM, Wilfert CM, Mwango A, Levy J, Abrams EJ, Bulterys M, Stringer JS. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA. 2007 Oct 24;298(16):1888-99.</citation>
    <PMID>17954540</PMID>
  </reference>
  <reference>
    <citation>Fowler MG, Coovadia H, Herron CM, Maldonado Y, Chipato T, Moodley D, Musoke P, Aizire J, Manji K, Stranix-Chibanda L, Fawzi W, Chetty V, Msweli L, Kisenge R, Brown E, Mwatha A, Eshleman SH, Richardson P, Allen M, George K, Andrew P, Zwerski S, Mofenson LM, Jackson JB; HPTN 046 Protocol Team. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):366-74. doi: 10.1097/QAI.0000000000000052.</citation>
    <PMID>24189151</PMID>
  </reference>
  <reference>
    <citation>Jamieson DJ, Chasela CS, Hudgens MG, King CC, Kourtis AP, Kayira D, Hosseinipour MC, Kamwendo DD, Ellington SR, Wiener JB, Fiscus SA, Tegha G, Mofolo IA, Sichali DS, Adair LS, Knight RJ, Martinson F, Kacheche Z, Soko A, Hoffman I, van der Horst C; BAN study team. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial. Lancet. 2012 Jun 30;379(9835):2449-58. doi: 10.1016/S0140-6736(12)60321-3. Epub 2012 Apr 26.</citation>
    <PMID>22541418</PMID>
  </reference>
  <reference>
    <citation>Kumwenda NI, Hoover DR, Mofenson LM, Thigpen MC, Kafulafula G, Li Q, Mipando L, Nkanaunena K, Mebrahtu T, Bulterys M, Fowler MG, Taha TE. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008 Jul 10;359(2):119-29. doi: 10.1056/NEJMoa0801941. Epub 2008 Jun 4.</citation>
    <PMID>18525035</PMID>
  </reference>
  <reference>
    <citation>Six Week Extended-Dose Nevirapine (SWEN) Study Team, Bedri A, Gudetta B, Isehak A, Kumbi S, Lulseged S, Mengistu Y, Bhore AV, Bhosale R, Varadhrajan V, Gupte N, Sastry J, Suryavanshi N, Tripathy S, Mmiro F, Mubiru M, Onyango C, Taylor A, Musoke P, Nakabiito C, Abashawl A, Adamu R, Antelman G, Bollinger RC, Bright P, Chaudhary MA, Coberly J, Guay L, Fowler MG, Gupta A, Hassen E, Jackson JB, Moulton LH, Nayak U, Omer SB, Propper L, Ram M, Rexroad V, Ruff AJ, Shankar A, Zwerski S. Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials. Lancet. 2008 Jul 26;372(9635):300-13. doi: 10.1016/S0140-6736(08)61114-9.</citation>
    <PMID>18657709</PMID>
  </reference>
  <reference>
    <citation>Fillekes Q, Mulenga V, Kabamba D, Kankasa C, Thomason MJ, Cook A, Chintu C, Gibb DM, Walker AS, Burger DM; CHAPAS-1 trial team. Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? AIDS. 2013 Aug 24;27(13):2111-5. doi: 10.1097/QAD.0b013e3283620811.</citation>
    <PMID>23595153</PMID>
  </reference>
  <reference>
    <citation>Patel K, Van Dyke RB, Mittleman MA, Colan SD, Oleske JM, Seage GR 3rd; International Maternal Pediatric Adolescent AIDS Clinical Trials 219219C Study Team. The impact of HAART on cardiomyopathy among children and adolescents perinatally infected with HIV-1. AIDS. 2012 Oct 23;26(16):2027-37. doi: 10.1097/QAD.0b013e3283578bfa.</citation>
    <PMID>22781228</PMID>
  </reference>
  <reference>
    <citation>Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M; Pediatric AIDS Clinical Trials Group. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother. 2007 Dec;51(12):4297-302. Epub 2007 Sep 24.</citation>
    <PMID>17893155</PMID>
  </reference>
  <reference>
    <citation>McArthur MA, Kalu SU, Foulks AR, Aly AM, Jain SK, Patel JA. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J. 2009 Dec;28(12):1127-9. doi: 10.1097/INF.0b013e3181acd17e.</citation>
    <PMID>19820426</PMID>
  </reference>
  <reference>
    <citation>Lopriore E, Rozendaal L, Gelinck LB, Bökenkamp R, Boelen CC, Walther FJ. Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. AIDS. 2007 Nov 30;21(18):2564-5.</citation>
    <PMID>18025905</PMID>
  </reference>
  <reference>
    <citation>Nagot N, Kankasa C, Meda N, Hofmeyr J, Nikodem C, Tumwine JK, Karamagi C, Sommerfelt H, Neveu D, Tylleskär T, Van de Perre P; PROMISE-PEP group. Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174. BMC Infect Dis. 2012 Oct 6;12:246. doi: 10.1186/1471-2334-12-246.</citation>
    <PMID>23039034</PMID>
  </reference>
  <reference>
    <citation>Chadwick EG, Pinto J, Yogev R, Alvero CG, Hughes MD, Palumbo P, Robbins B, Hazra R, Serchuck L, Heckman BE, Purdue L, Browning R, Luzuriaga K, Rodman J, Capparelli E; International Maternal Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J. 2009 Mar;28(3):215-9. doi: 10.1097/INF.0b013e31818cc053.</citation>
    <PMID>19209098</PMID>
  </reference>
  <reference>
    <citation>Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, Powis K, Dryden-Peterson S, Creek T, Jimbo W, Madidimalo T, Makhema J, Essex M, Shapiro RL. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012 Dec 1;206(11):1695-705. doi: 10.1093/infdis/jis553. Epub 2012 Oct 12.</citation>
    <PMID>23066160</PMID>
  </reference>
  <reference>
    <citation>Matthews LT, Ribaudo HJ, Parekh NK, Chen JY, Binda K, Ogwu A, Makhema J, Souda S, Lockman S, Essex M, Shapiro RL. Birth weight for gestational age norms for a large cohort of infants born to HIV-negative women in Botswana compared with norms for U.S.-born black infants. BMC Pediatr. 2011 Dec 16;11:115. doi: 10.1186/1471-2431-11-115.</citation>
    <PMID>22176889</PMID>
  </reference>
  <reference>
    <citation>Henrich TJ, Gallien S, Li JZ, Pereyra F, Kuritzkes DR. Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR. J Virol Methods. 2012 Dec;186(1-2):68-72. doi: 10.1016/j.jviromet.2012.08.019. Epub 2012 Sep 4.</citation>
    <PMID>22974526</PMID>
  </reference>
  <reference>
    <citation>Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, Gallien S, Lin NH, Giguel FF, Lavoie L, Ho VT, Armand P, Soiffer RJ, Sagar M, Lacasce AS, Kuritzkes DR. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 1;207(11):1694-702. doi: 10.1093/infdis/jit086. Epub 2013 Mar 4.</citation>
    <PMID>23460751</PMID>
  </reference>
  <reference>
    <citation>Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 2007 Apr;3(4):e46.</citation>
    <PMID>17411338</PMID>
  </reference>
  <reference>
    <citation>Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 2003 Oct;41(10):4531-6.</citation>
    <PMID>14532178</PMID>
  </reference>
  <reference>
    <citation>Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, Volpi R, Lusso P. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc. 2008;3(7):1240-8. doi: 10.1038/nprot.2008.108.</citation>
    <PMID>18600229</PMID>
  </reference>
  <reference>
    <citation>Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol. 2002 Apr;76(8):3739-47.</citation>
    <PMID>11907213</PMID>
  </reference>
  <reference>
    <citation>Brussel A, Mathez D, Broche-Pierre S, Lancar R, Calvez T, Sonigo P, Leibowitch J. Longitudinal monitoring of 2-long terminal repeat circles in peripheral blood mononuclear cells from patients with chronic HIV-1 infection. AIDS. 2003 Mar 28;17(5):645-52.</citation>
    <PMID>12646786</PMID>
  </reference>
  <reference>
    <citation>Yukl SA, Shergill AK, McQuaid K, Gianella S, Lampiris H, Hare CB, Pandori M, Sinclair E, Günthard HF, Fischer M, Wong JK, Havlir DV. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS. 2010 Oct 23;24(16):2451-60. doi: 10.1097/QAD.0b013e32833ef7bb.</citation>
    <PMID>20827162</PMID>
  </reference>
  <reference>
    <citation>Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, Bosch RJ, Lai J, Chioma S, Emad F, Abdel-Mohsen M, Hoh R, Hecht F, Hunt P, Somsouk M, Wong J, Johnston R, Siliciano RF, Richman DD, O'Doherty U, Palmer S, Deeks SG, Siliciano JD. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog. 2013 Feb;9(2):e1003174. doi: 10.1371/journal.ppat.1003174. Epub 2013 Feb 14.</citation>
    <PMID>23459007</PMID>
  </reference>
  <reference>
    <citation>Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest. 2011 Apr;121(4):1549-60. doi: 10.1172/JCI44539. Epub 2011 Mar 14.</citation>
    <PMID>21403397</PMID>
  </reference>
  <reference>
    <citation>Buzon MJ, Seiss K, Weiss R, Brass AL, Rosenberg ES, Pereyra F, Yu XG, Lichterfeld M. Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol. 2011 Sep;85(18):9646-50. doi: 10.1128/JVI.05327-11. Epub 2011 Jul 6.</citation>
    <PMID>21734042</PMID>
  </reference>
  <reference>
    <citation>Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004 Feb;48(2):437-43.</citation>
    <PMID>14742192</PMID>
  </reference>
  <reference>
    <citation>Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA, Sullivan JL. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998 Aug;178(2):368-74.</citation>
    <PMID>9697716</PMID>
  </reference>
  <reference>
    <citation>Mirochnick M, Thomas T, Capparelli E, Zeh C, Holland D, Masaba R, Odhiambo P, Fowler MG, Weidle PJ, Thigpen MC. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother. 2009 Mar;53(3):1170-6. doi: 10.1128/AAC.01117-08. Epub 2008 Dec 29.</citation>
    <PMID>19114673</PMID>
  </reference>
  <reference>
    <citation>Kumar PN, Sweet DE, McDowell JA, Symonds W, Lou Y, Hetherington S, LaFon S. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 1999 Mar;43(3):603-8.</citation>
    <PMID>10049274</PMID>
  </reference>
  <reference>
    <citation>Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14;363(16):1510-20. doi: 10.1056/NEJMoa1000931.</citation>
    <PMID>20942667</PMID>
  </reference>
  <reference>
    <citation>Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, Chi BH, Cotton MF, Moultrie H, Khadse S, Schimana W, Bobat R, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Palumbo P. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012 Jun 21;366(25):2380-9. doi: 10.1056/NEJMoa1113249.</citation>
    <PMID>22716976</PMID>
  </reference>
  <reference>
    <citation>Chadwick EG, Yogev R, Alvero CG, Hughes MD, Hazra R, Pinto JA, Robbins BL, Heckman BE, Palumbo PE, Capparelli EV; International Pediatric Adolescent Clinical Trials Group (IMPAACT) P1030 Team. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS. 2011 Mar 13;25(5):643-9. doi: 10.1097/QAD.0b013e32834403f6.</citation>
    <PMID>21297419</PMID>
  </reference>
  <reference>
    <citation>Bendall SC, Simonds EF, Qiu P, Amir el-AD, Krutzik PO, Finck R, Bruggner RV, Melamed R, Trejo A, Ornatsky OI, Balderas RS, Plevritis SK, Sachs K, Pe'er D, Tanner SD, Nolan GP. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011 May 6;332(6030):687-96. doi: 10.1126/science.1198704.</citation>
    <PMID>21551058</PMID>
  </reference>
  <reference>
    <citation>Kainonen E, Rautava S, Isolauri E. Immunological programming by breast milk creates an anti-inflammatory cytokine milieu in breast-fed infants compared to formula-fed infants. Br J Nutr. 2013 Jun;109(11):1962-70. doi: 10.1017/S0007114512004229. Epub 2012 Oct 30.</citation>
    <PMID>23110822</PMID>
  </reference>
  <reference>
    <citation>Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001 Oct 19;15(15):1951-7.</citation>
    <PMID>11600822</PMID>
  </reference>
  <reference>
    <citation>Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther. 1999 Jul;66(1):16-24.</citation>
    <PMID>10430105</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harvard School of Public Health</investigator_affiliation>
    <investigator_full_name>Roger Shapiro</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Botswana</keyword>
  <keyword>Immunology</keyword>
  <keyword>Antiretroviral Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Nevirapine</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

